Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PETALUMA, Calif., June 6, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences (Nasdaq:OCLS) announced today that the company has entered into two key agreements, which establish the license and supply as well as shared services with its wholly owned subsidiary, Ruthigen, Inc., which is focused on the discovery, development, and commercialization of pharmaceutical-grade hypochlorous acid-based therapeutics. The company expects to negotiate and enter into a third agreement (Separation Agreement) governing other terms of their business relationship. The effective date for all three agreements would be the closing date of Ruthigen’s proposed initial public offering, if any should occur.
Help employers find you! Check out all the jobs and post your resume.
